Should Growth Investors Buy This Little-Known Stock?
Risk and reward are often correlated. Investing in stock entails risk, but it also offers the opportunity for investors to build wealth and purchasing power over time.
Part of the risk associated with owning stocks is that they can be quite volatile. For instance, the Nasdaq Composite has dipped roughly 30% in 2022. And the genomic-test maker Veracyte (NASDAQ: VCYT) has seen its stock plunge a whopping 60% during that time. For investors who are unfamiliar with the company, its products are used to diagnose cancer found in the breast, colon, lungs, and thyroid.
But is the small-cap stock a buy for growth investors? Here's a look at Veracyte's fundamentals and valuation to help investors decide for themselves.
Source Fool.com
